Search Results

You are looking at 131 - 140 of 455 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

good PS. The CALGB 9633 trial assessed paclitaxel and carboplatin in patients with T2, N0, M0, stage IB lung cancer; 185 updated results have been reported. 186 , 187 In this trial, 344 patients (aged 34–81 years) were randomly assigned to either

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory

include platinum agents (cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), vinorelbine, vinblastine, etoposide, pemetrexed, and gemcitabine. Combinations using many of these drugs produce 1-year survival rates of 30% to 40% and are superior to

Full access

Noa Efrat Ben-Baruch, Ron Bose, Shyam M. Kavuri, Cynthia X. Ma, and Matthew J. Ellis

for HER2 -mutated breast cancer should be considered in the future. Phase I trials of neratinib with paclitaxel, capecitabine, or vinorelbine have demonstrated that these combinations are safe 8 – 10 ; neratinib has also been combined with other

Full access

Lauren Nye, Timothy K. Huyck, and William J. Gradishar

count recovery before delivery. After delivery, the patient will be offered paclitaxel therapy every 2 weeks for 4 doses followed by surgical management. Both breast-conserving therapy and mastectomy were discussed with patient. Genetic testing was

Full access

public interest and attention, Dr. Carlson reviewed the research and evidence leading to the decision for the NCCN Guidelines Panel to reaffirm its existing recommendation of bevacizumab (Avastin, Genentech/Roche) in combination with paclitaxel (Taxol

Full access

Charu Aggarwal, Neeta Somaiah, and George R. Simon

survival than those without acne-like rash ( P < .001). 48 Therefore, the presence of rash seems to be the best predictor of clinical benefit for patients treated with cetuximab. In a similarly designed BMS-099 trial that compared carboplatin/paclitaxel

Full access

/TPI (35 mg/m 2 twice daily) and oxaliplatin (85 mg/m 2 ) before undergoing concurrent chemoradiation (standard-of-care radiation dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve 2) and paclitaxel (50

Full access

will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants and documented in

Full access

Presenter: Deborah K. Armstrong

The study’s first arm was placebo + carboplatin/paclitaxel followed by placebo as maintenance. Arm 2 was veliparib + carboplatin/paclitaxel followed by placebo. Arm 3 was veliparib + carboplatin/paclitaxel followed by veliparib maintenance. An

Full access

dose of 5,040 cGy will be used at all participating study sites) with carboplatin (area under the curve, 2) and paclitaxel (50 mg/m2) for 6 weeks, followed by surgery. FTD/TPI will be self-administered (in tablet form) twice daily by study participants